Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Melanoma 13Colorectal Neoplasms 5Neoplasm Metastasis 4Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Solid Tumors Harboring a BRAF V600 Mutation 1Skin Neoplasms 1Skin Diseases 1Pancreatic Neoplasms 1Lymphatic Metastasis 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Glioblastoma 1Astrocytoma 1Advanced BRAF Mutant Cancers 1

Interventions

Gemcitabine 153Fluorouracil 45Capecitabine 45130-nm albumin-bound paclitaxel 43Oxaliplatin 42Albumin-Bound Paclitaxel 39Leucovorin 31Erlotinib Hydrochloride 30pembrolizumab 23Radiotherapy 22Irinotecan 22Radiosurgery 20Bevacizumab 19Docetaxel 17Cyclophosphamide 17Taxes 13Cisplatin 13Cetuximab 13folfirinox 12Nivolumab 11Surgical Procedures, Operative 7Paclitaxel 7Ipilimumab 7dehydroftorafur 6Standard of Care 6Radiation 6Magnetic Resonance Spectroscopy 6spartalizumab 5ruxolitinib 5durvalumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pancreatic Neoplasms × encorafenib × Clear all
NCT04390243 2024-05-06

Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation

Academic and Community Cancer Research United

Phase 2 Terminated
6 enrolled 16 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡